Linda Rubinstein

CFO

Equibles does not estimate personal net worth.

Get an email with a short summary when Nektar Therapeutics publishes a filing, an earnings call transcript or a press release.

Get NKTR alerts

About Linda Rubinstein

Linda Rubinstein is recorded as CFO at Nektar Therapeutics (NKTR) since May 15, 2026. Nektar Therapeutics reported in an 8-K filed May 8, 2026 that Linda Rubinstein was appointed interim Chief Financial Officer and the principal financial and accounting officer, effective May 15, 2026. Linda Rubinstein has spoken on 2 earnings calls across 1 company, most recently for Nektar Therapeutics on November 12, 2026. Nektar Therapeutics is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nektar Therapeutics includes Howard Robin (CEO), Sandra Gardiner (CFO), Jillian Thomsen (Chief Accounting Officer) and 1 other.

“Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.”

Nektar Therapeutics Form 8-K, filed May 8, 2026 · Read the filing

Linda Rubinstein on recent calls

“On today's call, I'll review our quarterly financials for the third quarter of 2026 and updates to our 2026 financial guidance. We ended the third quarter of 2026 with approximately $953 million in cash and investments with no debt on our balance sheet.”

CFO, Nektar Therapeutics Q3 2026 Financial Results · November 12, 2026

“On today's call, I'll review our quarterly financials for the second quarter of 2026 and our 2026 financial guidance. We ended the second quarter of 2026 with $1.02 billion in cash and investments with no debt on our balance sheet.”

CFO, Nektar Therapeutics Q2 FY2026 Earnings Call · August 13, 2026